Article Text

Download PDFPDF
A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome
  1. Leopoldo Baiza-Durán1,
  2. Javier Medrano-Palafox1,
  3. Everardo Hernández-Quintela2,
  4. Jaime Lozano-Alcazar3,
  5. J Félix Alaníz-de la O4
  1. 1Clinical Research Department, Laboratorios Sophia, S.A. de C.V. Guadalajara, Jalisco, México
  2. 2Asociación para Evitar la Ceguera en México, Hospital Dr. Luis Sánchez Bulnes. México D.F., México
  3. 3Fundación Hospital “Nuestra Señora de la Luz” I.A.P. México D.F., México
  4. 4Antiguo Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Unidad de Oftalmología, Guadalajara, Jalisco, México
  1. Correspondence to Dr Leopoldo Baiza-Durán, Laboratorios Sophia, S.A. de C.V., Av. Paseo del Norte 5255, Guadalajara Technology Park, C.P. 45010, Zapopan, Jalisco, México; drbvista{at}


Objective To evaluate the efficacy and safety of two different concentrations of cyclosporine A (CsA) in aqueous solution compared to vehicle in patients with dry eye syndrome.

Design Multicentre, randomised, double-masked, vehicle-controlled, clinical trial.

Methods A total of 183 patients were enrolled and randomised to either CsA 1% (group A), CsA 0.05% (group B) or vehicle only (group C). The main objective was to evaluate the efficacy of CsA aqueous solution in the reduction of signs and symptoms in patients with moderate to severe dry eye disease.

Results An early (day 21) statistically significant improvement (p<0.05) was evident in four symptoms and three ocular signs in group A. An equivalent improvement in three symptoms and three ocular signs was demonstrated in group B. A significant improvement was identified in two symptoms and two ocular signs in group C. Comparing the three groups together, group A performed better in four symptoms than group B did with just one symptom. Group C did not show significant improvement. At day 42, group A showed improvement in four symptoms, while group B showed improvement in one symptom and one ocular sign.

Conclusions Cyclosporine A reduced complaints and improved major ocular signs in patients with moderate-to-severe dry eye disease. The group treated with the 0.1% cyclosporine A aqueous solution outperformed the other groups.

  • Dry eye
  • cyclosporine
  • keratoconjunctivitis sicca
  • comparative clinical trial
  • occular surface
  • cornea
  • medical treatment
  • cyclosporine 0.1%

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests LB-D and JM-P are employees of the Clinical Research Department of Laboratorios Sophia, S.A. de C.V., which manufactures and distributes the cyclosporine aqueous solution. The other authors have no competing interests.

  • Ethics approval This study was conducted with the approval of the Ethics Committees of the following hospitals: Hospital “Dr. Luis Sánchez Bulnes” of the Asociación para Evitar la Ceguera en México, I.A.P., México D.F., México; Fundación Hospital “Nuestra Señora de la Luz” I.A.P. México, D.F., México; and Antiguo Hospital Civil de Guadalajara “Fray Antonio Alcalde”, Unidad de Oftalmología; Guadalajara, Jalisco, México.

  • Provenance and peer review Not commissioned; externally peer reviewed.